Agilent Technologies Introduces miRNA Microarray Labelling and Hybridization Kit
News Aug 04, 2008
Agilent Technologies Inc. has introduced a new labelling and hybridization kit that simplifies the protocol for running miRNA profiling experiments on Agilent oligonucleotide microarrays.
The new kit, scheduled to ship in late July, contains all the reagents and buffer needed to label and hybridize 24 miRNA microarray experiments. Agilent’s microarray-based tools for studying miRNAs combine a unique direct labelling method with innovative probe design.
The result is a robust, highly sensitive platform that allows broad insight into expression and regulation of all known human, mouse and rat miRNAs. The system’s dynamic range spans greater than 5 logs for comprehensive miRNA expression profiling, and sample input is only 100 nanograms.
“We continue to invest in the miRNA platform, and this second-generation kit is the latest example of this emphasis at Agilent,” said Sangita Parikh, Agilent miRNA product manager. “In the year since we launched miRNA microarray products, the platform has achieved enthusiastic acceptance, and this is part of Agilent’s ongoing strategy to drive growth in emerging microarray applications.”
Agilent miRNA microarrays are configured with eight experiments per standard 1 in. x 3 in. slide, and three slides are included in each kit. This multiplex configuration minimizes in terms of purchase price, handling and reagents. Each experiment requires just 100 nanograms total RNA input per labelling reaction.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.